Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment.
- 1 January 2000
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 32 (2) , 128-133
- https://doi.org/10.3109/07853890009011762
Abstract
Pharmacogenetic research into neurotransmitter-related genes is helping to unravel genetic factors that determine antipsychotic response. Several genetic mutations in neurotransmitter receptors targeted by antipsychotic drugs have been found to be related to clinical response. Modern molecular genetic techniques will facilitate the identification of those mutations that determine treatment response. Future psychiatric prescription will include the genetic characterization of neurotransmitter receptors for the selection of the most beneficial drug according to the individual's pharmacogenetic profile.Keywords
This publication has 41 references indexed in Scilit:
- Genetic Variation in Human 5-HT Receptors: Potential Pathogenetic and Pharmacological RoleaAnnals of the New York Academy of Sciences, 1998
- Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia PatientsNeuropsychopharmacology, 1998
- Pharmacogenomics and diagnosticsNature Biotechnology, 1998
- Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine responseSchizophrenia Research, 1998
- Pharmacogenomics: Will the regulators approve?Nature Biotechnology, 1998
- Dopamine D4 ReceptorsCNS Drugs, 1997
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- Review the role of dopamine D4 receptors in schizophrenia and antipsychotic actionJournal of Psychiatric Research, 1997
- Clozapine response and the 5HT2C Cys23Ser polymorphismNeuroReport, 1996
- Association between clozapine response and allelic variation in the 5-HT2C receptor geneNeuroReport, 1995